ecrin-mdr-crcClinical2022Colorectal cancerColorectal CancerObservationalhttps://newmdr.ecrin.org/Study/40540China7ECRIN MDRCompletedfalseClinical data analysis of bevacizumab-induced hypertension in patients with colorectal cancerInterventions: None:None Primary outcome(s): Blood pressure;Overall survival;Progress-free survival;Blood pressure from 2 months before treatment to 6 months after treatment, or before treatment with other VEGF inhibitors and other pressors;The use of bevacizumab, atropine, irinotecan and antihypertensive drugs Study Design: Sequential2022-07-1540540ChiCTR2200061510